论文部分内容阅读
目的观察贝伐珠单抗(BV)联合化疗治疗HER2阴性进展期乳腺癌的疗效和安全性。方法回顾性分析接受贝伐株单抗治疗的15例进展期乳腺癌患者的临床资料,按照实体肿瘤疗效评价标准(RECIST1.1)和美国国立癌症研究所不良反应事件通用术语标准评价疗效和不良反应,每2个月评估疗效,主要观察终点是无进展生存期(progression free survival,PFS),每个周期评价不良反应。结果 15例患者的中位PFS为4个月;治疗10个周期以上的患者为4例,6个周期以上者3例,其余8例均不足4个周期;15例患者均可评价疗效,5例(33.33%)PR中4例伴胸壁转移;5例SD(33.33%),5例PD(33.33%);主要不良反应为高血压4例、少量鼻出血3例、蛋白尿2例、贫血2例、血小板减少2例,经对症治疗后均好转,4例停药。结论贝伐珠单抗联合化疗作为二线及以上方案治疗进展期乳腺癌仍有一定疗效,对于伴胸壁转移的患者疗效尤其显著,不良反应可耐受。
Objective To observe the efficacy and safety of bevacizumab (BV) combined with chemotherapy in the treatment of HER2-negative advanced breast cancer. Methods The clinical data of 15 patients with advanced breast cancer who underwent bevacizumab treatment were retrospectively analyzed. The efficacy and adverse reactions were evaluated according to RECIST1.1 standard and the common terminology standard of adverse events of the National Cancer Institute. The efficacy was evaluated every 2 months. The primary end point was progression free survival (PFS), with adverse reactions assessed on a weekly basis. Results The median PFS of 15 patients was 4 months; 4 patients were treated more than 10 cycles, 3 patients were more than 6 cycles, and the remaining 8 patients were less than 4 cycles; 15 patients were evaluated for efficacy, 5 Four patients with PR (33.33%) had chest wall metastases. Five patients had SD (33.33%) and five patients had PD (33.33%). The main adverse reactions were hypertension, 3 cases of minor nosebleeds, 2 cases of proteinuria, 2 cases, thrombocytopenia in 2 cases, after symptomatic treatment were improved, 4 cases discontinued. Conclusion Bevacizumab combined with chemotherapy as a second-line and above treatment of advanced breast cancer still have a certain effect, especially for patients with chest wall metastasis, adverse reactions can tolerate.